These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 12455185)

  • 1. Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease.
    Wigler N; Shina S; Kaplan O; Luboshits G; Chaitchik S; Keydar I; Ben-Baruch A
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):940-3. PubMed ID: 12455185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma.
    Luboshits G; Shina S; Kaplan O; Engelberg S; Nass D; Lifshitz-Mercer B; Chaitchik S; Keydar I; Ben-Baruch A
    Cancer Res; 1999 Sep; 59(18):4681-7. PubMed ID: 10493525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity.
    Azenshtein E; Luboshits G; Shina S; Neumark E; Shahbazian D; Weil M; Wigler N; Keydar I; Ben-Baruch A
    Cancer Res; 2002 Feb; 62(4):1093-102. PubMed ID: 11861388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions.
    Soria G; Yaal-Hahoshen N; Azenshtein E; Shina S; Leider-Trejo L; Ryvo L; Cohen-Hillel E; Shtabsky A; Ehrlich M; Meshel T; Keydar I; Ben-Baruch A
    Cytokine; 2008 Oct; 44(1):191-200. PubMed ID: 18790652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.
    Yaal-Hahoshen N; Shina S; Leider-Trejo L; Barnea I; Shabtai EL; Azenshtein E; Greenberg I; Keydar I; Ben-Baruch A
    Clin Cancer Res; 2006 Aug; 12(15):4474-80. PubMed ID: 16899591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
    Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
    Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
    Vaday GG; Peehl DM; Kadam PA; Lawrence DM
    Prostate; 2006 Feb; 66(2):124-34. PubMed ID: 16161154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
    Gentilini O; Masullo M; Rotmensz N; Peccatori F; Mazzarol G; Smeets A; Simsek S; De Dosso S; Veronesi P; Intra M; Zurrida S; Viale G; Goldhirsch A; Veronesi U
    Eur J Surg Oncol; 2005 Apr; 31(3):232-6. PubMed ID: 15780556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
    Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
    Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
    Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
    Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
    Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression.
    Nagai MA; Fregnani JH; Netto MM; Brentani MM; Soares FA
    Breast Cancer Res Treat; 2007 Nov; 106(1):49-56. PubMed ID: 17211533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C.
    Nischalke HD; Nattermann J; Fischer HP; Sauerbruch T; Spengler U; Dumoulin FL
    Mediators Inflamm; 2004 Dec; 13(5-6):357-9. PubMed ID: 15770052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.